MESSAGE FROM THE DIRECTOR OF RESEARCH
Since recently taking on the role as permanent Director of Research at the Kolling Institute, I’m really pleased to be working with our joint venture partners – the University of Sydney and the Northern Sydney Local Health District. It’s an important time for translational medical research in Australia and I look forward to supporting and promoting the excellent work that we are doing here. A key part of our success relies on access to core facilities and state-of-the-art equipment and it’s encouraging to see the Kolling’s mass spectrometry core lab has now been officially launched. It will give our researchers, especially those working in the field of bowel cancer, the chance to work with world-leading technology and experts like Professor Mark Molloy. It’s a great example of how we are embracing new technologies to influence our research practices and patient outcomes. An important priority moving forward will be the development of the Kolling Institute’s Research Strategy. This will be a valuable body of work to provide a road map for our medical research into the future, and help ensure our efforts lead to improved health
outcomes for patients. I am also pleased to announce the
successful recipients of a new program to support early to mid-career researchers with their travel expenses. Bryony Winters from the Pain Management Research Institute, and Kelly McKelvey and Yaser Hadi Gholami from the Bill Walsh Translational Cancer Research Lab, which are both part of the Kolling, successfully applied for the Beryl and Jack Jacobs Travel Award. It’s aimed at promoting the cutting edge research performed at the Kolling, as well as building collaborative links with our international partners. The award has been generously supported by the Skipper Jacobs Charitable Trust. Finally, I recently returned from the World Parkinson Congress in Kyoto where I had the opportunity to hear and talk to Nobel Prize winner Shinya Yamanaka. It was a wonderful opportunity to be part of an event with representatives from over 60 countries. The congress was well attended by clinicians and scientists and patients, all engaged with the recent discoveries in Parkinson’s disease research.
2
KOLLINGNEWS |ISSUE 2| JUNE 2019
Made with FlippingBook - professional solution for displaying marketing and sales documents online